Cartesian Therapeutics Inc. (RNAC)
Healthcare
Biotechnology
7.80 $
+0.9%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Cartesian Therapeutics Inc. (RNAC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 36.2% of the shares are freely tradable; institutional investors hold 24.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
24.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
53.7%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
36.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
14.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
29Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Squarepoint Ops LLC | 7.62 | 2,238,486 | +12,190.6 | 03/31/2026 |
| FMR Inc | 2.72 | 799,743 | -41.5 | 03/31/2026 |
| BlackRock Inc | 2.04 | 599,108 | -1.7 | 03/31/2026 |
| Vanguard Group Inc | 1.84 | 541,228 | +3.9 | 12/31/2025 |
| Vanguard Capital Management, LLC | 1.39 | 407,597 | +0.0 | 03/31/2026 |
| 683 Capital Management LLC | 1.12 | 330,000 | +17.9 | 03/31/2026 |
| Millennium Management LLC | 0.97 | 284,317 | +73.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 1.41 | 415,234 | +0.0 | 03/31/2026 |
| Fidelity Select Biotechnology | 1.25 | 366,554 | +0.0 | 04/30/2026 |
| Vanguard Total Stock Mkt Idx Inv | 0.96 | 280,909 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.